X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6375) 6375
Publication (583) 583
Book Review (89) 89
Book Chapter (65) 65
Newsletter (39) 39
Book / eBook (9) 9
Dissertation (9) 9
Conference Proceeding (5) 5
Magazine Article (4) 4
Data Set (3) 3
Newspaper Article (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4928) 4928
index medicus (3840) 3840
oncology (3065) 3065
adenocarcinoma (2728) 2728
female (2703) 2703
cancer (2523) 2523
male (1889) 1889
middle aged (1779) 1779
aged (1521) 1521
chemotherapy (1491) 1491
animals (1429) 1429
tumors (1390) 1390
adenocarcinoma - pathology (1325) 1325
research (1278) 1278
adenocarcinoma - drug therapy (1227) 1227
adult (1194) 1194
cell line, tumor (1181) 1181
metastasis (1105) 1105
prognosis (1061) 1061
care and treatment (1046) 1046
mice (1013) 1013
apoptosis (1000) 1000
expression (966) 966
gene expression (908) 908
carcinoma (903) 903
lung cancer (898) 898
medicine (893) 893
cancer therapies (892) 892
research article (891) 891
genetic aspects (887) 887
health aspects (887) 887
pancreatic cancer (837) 837
multidisciplinary sciences (806) 806
survival (778) 778
proteins (751) 751
mutation (719) 719
adenocarcinoma - genetics (708) 708
medical prognosis (664) 664
science (663) 663
kinases (653) 653
adenocarcinoma - metabolism (649) 649
antineoplastic combined chemotherapy protocols - therapeutic use (649) 649
neoplasm staging (624) 624
treatment outcome (624) 624
surgery (595) 595
development and progression (593) 593
aged, 80 and over (587) 587
immunohistochemistry (573) 573
lung neoplasms - pathology (563) 563
studies (553) 553
therapy (546) 546
analysis (541) 541
pathology (527) 527
patients (520) 520
lung neoplasms - drug therapy (519) 519
diagnosis (518) 518
biology (488) 488
antineoplastic agents - therapeutic use (486) 486
cell biology (477) 477
colorectal cancer (464) 464
lung neoplasms - genetics (458) 458
metastases (458) 458
article (457) 457
gene expression regulation, neoplastic (455) 455
risk factors (454) 454
breast-cancer (447) 447
breast cancer (442) 442
ovarian neoplasms - drug therapy (434) 434
cell cycle (429) 429
antineoplastic agents - pharmacology (428) 428
adenocarcinoma, clear cell - drug therapy (427) 427
medical research (424) 424
ovarian cancer (422) 422
cell proliferation (421) 421
signal transduction (421) 421
survival rate (413) 413
biochemistry & molecular biology (411) 411
pancreatic neoplasms - pathology (409) 409
drug therapy (402) 402
apoptosis - drug effects (397) 397
medicine, research & experimental (394) 394
biomarkers (388) 388
growth (385) 385
ovarian neoplasms - pathology (378) 378
physiological aspects (376) 376
neoplasms. tumors. oncology. including cancer and carcinogens (373) 373
cell proliferation - drug effects (369) 369
cells (365) 365
cell growth (359) 359
retrospective studies (357) 357
usage (352) 352
gastroenterology & hepatology (351) 351
mice, nude (346) 346
genetics (340) 340
gemcitabine (337) 337
cancers and neoplasms (333) 333
inhibition (333) 333
cisplatin (325) 325
adenocarcinoma, clear cell - pathology (323) 323
pancreatic neoplasms - drug therapy (320) 320
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6410) 6410
Japanese (43) 43
French (12) 12
Chinese (9) 9
German (9) 9
Spanish (5) 5
Italian (2) 2
Polish (2) 2
Hungarian (1) 1
Russian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Clinical Oncology, ISSN 0732-183X, 12/2015, Volume 33, Issue 34, pp. 4015 - 4022
Journal Article
Nature Communications, ISSN 2041-1723, 2015, Volume 6, Issue 1, p. 6118
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 07/2012, Volume 30, Issue 21, pp. 2654 - 2663
Purpose The frequency of BRCA1 and BRCA2 germ-line mutations in women with ovarian cancer is unclear; reports vary from 3% to 27%. The impact of germ-line... 
POLY(ADP-RIBOSE) POLYMERASE | CLEAR-CELL | ONCOLOGY | RESISTANCE | IMPROVED SURVIVAL | HOMOLOGOUS RECOMBINATION | CARCINOMA | CARRIERS | TUMORS | CHEMOTHERAPY | FEATURES | Medical History Taking | Recurrence | Prospective Studies | Humans | Middle Aged | Ovarian Neoplasms - pathology | Drug Resistance, Neoplasm | Cystadenocarcinoma, Serous - genetics | Cystadenocarcinoma, Serous - drug therapy | Case-Control Studies | Ovarian Neoplasms - genetics | Peritoneal Neoplasms - drug therapy | Neoplasm Grading | Fallopian Tube Neoplasms - genetics | Aged, 80 and over | Genes, BRCA2 | Germ-Line Mutation | Adult | Female | Genes, BRCA1 | Ovarian Neoplasms - drug therapy | Fallopian Tube Neoplasms - drug therapy | Carcinoma - drug therapy | Carcinoma, Endometrioid - genetics | Kaplan-Meier Estimate | Mutation Rate | Treatment Outcome | Carcinoma, Endometrioid - drug therapy | Australia - epidemiology | Ovarian Neoplasms - epidemiology | Disease-Free Survival | Point Mutation | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Peritoneal Neoplasms - genetics | Carcinoma - genetics | Aged | Platinum Compounds - administration & dosage | Neoplasm Staging | Adenocarcinoma, Clear Cell - genetics | Adenocarcinoma, Clear Cell - drug therapy | Cohort Studies | Original Reports | Gynecologic Cancer | Gync21 | Gync15
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2014, Volume 135, Issue 2, pp. 223 - 230
Abstract Objectives Complete surgery with no macroscopic residual disease (RD) at primary (PDS) or interval debulking surgery (IDS) is the main objective of... 
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | Neoadjuvant chemotherapy | Number of cycles | Interval surgery | Prognosis | Epithelial ovarian cancer | Number of cycles Prognosis | SURVIVAL | TRIALS | CYTOREDUCTIVE SURGERY | METAANALYSIS | SENSITIVITY | RESIDUAL DISEASE | OBSTETRICS & GYNECOLOGY | ONCOLOGY | ADVANCED-STAGE OVARIAN | RESISTANCE | PRIMARY DEBULKING SURGERY | CARCINOMA | Adenocarcinoma - pathology | Adenocarcinoma, Mucinous - pathology | Carcinosarcoma - surgery | Humans | Middle Aged | Ovarian Neoplasms - pathology | Cystadenocarcinoma, Serous - pathology | Cystadenocarcinoma, Serous - drug therapy | Cytoreduction Surgical Procedures | Young Adult | Carcinoma, Endometrioid - surgery | Adenocarcinoma, Mucinous - surgery | Aged, 80 and over | Adult | Female | Neoadjuvant Therapy | Retrospective Studies | Adenocarcinoma, Mucinous - drug therapy | Paclitaxel - administration & dosage | Ovarian Neoplasms - drug therapy | Adenocarcinoma, Clear Cell - surgery | Carcinosarcoma - pathology | Neoplasms, Glandular and Epithelial - pathology | Reoperation | Treatment Outcome | Carcinoma, Endometrioid - drug therapy | Adenocarcinoma - drug therapy | Cystadenocarcinoma, Serous - surgery | Neoplasms, Glandular and Epithelial - surgery | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms, Glandular and Epithelial - drug therapy | Carcinoma, Ovarian Epithelial | Adenocarcinoma, Clear Cell - pathology | Aged | Carcinosarcoma - drug therapy | Platinum Compounds - administration & dosage | Carcinoma, Endometrioid - pathology | Adenocarcinoma - surgery | Adenocarcinoma, Clear Cell - drug therapy | Cohort Studies | Ovarian Neoplasms - surgery | Cancer patients | Care and treatment | Surgery | Adjuvant treatment | Ovarian cancer | Cancer | Life Sciences
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2003, Volume 349, Issue 5, pp. 427 - 434
In this randomized trial, an antibody against vascular endothelial growth factor, bevacizumab, prolonged the time to progression of disease in patients with... 
MEDICINE, GENERAL & INTERNAL | INHIBITION | PROTEIN | THERAPY | ANGIOGENESIS | PRODUCT | TUMOR-SUPPRESSOR GENE | EMBRYONIC LETHALITY | CARCINOMA | EXPRESSION | HYPOXIA-INDUCIBLE FACTORS | Vascular Endothelial Growth Factor A | Kidney Neoplasms - genetics | Vascular Endothelial Growth Factors | Humans | Ligases - genetics | Middle Aged | Antibodies, Monoclonal - adverse effects | Carcinoma, Renal Cell - genetics | Antibodies, Monoclonal - therapeutic use | Male | Bevacizumab | Endothelial Growth Factors - immunology | Antibodies, Monoclonal, Humanized | Lymphokines - antagonists & inhibitors | Female | Carcinoma, Renal Cell - drug therapy | Genes, Tumor Suppressor | Double-Blind Method | Lymphatic Metastasis | Disease Progression | Endothelial Growth Factors - antagonists & inhibitors | Ubiquitin-Protein Ligases | Adenocarcinoma, Clear Cell - secondary | Neovascularization, Pathologic - drug therapy | Carcinoma, Renal Cell - secondary | Lymphokines - immunology | Kidney Neoplasms - pathology | Von Hippel-Lindau Tumor Suppressor Protein | Kidney Neoplasms - drug therapy | Adenocarcinoma, Clear Cell - genetics | Intercellular Signaling Peptides and Proteins - immunology | Tumor Suppressor Proteins | Adenocarcinoma, Clear Cell - drug therapy | Monoclonal antibodies | Drug therapy | Carcinoma, Renal cell | Proteins | Studies | Angiogenesis | Cytokines | Rodents | Mutation | Vascular endothelial growth factor | Cancer
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2011, Volume 17, Issue 8, pp. 2538 - 2548
Journal Article
Annals of Surgical Oncology, ISSN 1068-9265, 12/2012, Volume 19, Issue 13, pp. 4059 - 4067
To analyze the impact of radical cytoreductive surgery—as part of primary tumor debulking—on the amount of residual tumor and survival in patients with... 
Oncology | Medicine & Public Health | Surgical Oncology | Surgery | SURGERY | PROGNOSTIC-FACTOR | ONCOLOGY | RESECTION | CARCINOMA | Prognosis | Follow-Up Studies | Neoplasm, Residual - surgery | Endometrial Neoplasms - mortality | Adenocarcinoma, Clear Cell - mortality | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Gynecologic Surgical Procedures | Ovarian Neoplasms - mortality | Neoplasm Recurrence, Local - mortality | Cystadenocarcinoma, Serous - drug therapy | Neoplasm Recurrence, Local - surgery | Peritoneal Neoplasms - drug therapy | Neoplasm Grading | Adenocarcinoma, Mucinous - surgery | Adult | Female | Neoadjuvant Therapy | Chemotherapy, Adjuvant | Neoplasm, Residual - mortality | Adenocarcinoma, Mucinous - drug therapy | Ovarian Neoplasms - drug therapy | Adenocarcinoma, Clear Cell - surgery | Peritoneal Neoplasms - surgery | Survival Rate | Combined Modality Therapy | Lymphatic Metastasis | Peritoneal Neoplasms - mortality | Cystadenocarcinoma, Serous - surgery | Adenocarcinoma, Mucinous - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Endometrial Neoplasms - surgery | Neoplasm, Residual - drug therapy | Cystadenocarcinoma, Serous - mortality | Endometrial Neoplasms - drug therapy | Aged | Neoplasm Staging | Adenocarcinoma, Clear Cell - drug therapy | Ovarian Neoplasms - surgery | Chemotherapy | Analysis | Ovarian cancer | Cancer
Journal Article
British Journal of Cancer, ISSN 0007-0920, 04/2013, Volume 108, Issue 8, pp. 1553 - 1559
Journal Article
Gynecologic Oncology, ISSN 0090-8258, 2007, Volume 108, Issue 3, pp. 619 - 626
Abstract Objectives. Folate receptor α (FRα) is a folate-binding protein overexpressed on ovarian and several other epithelial malignancies that can be used as... 
Hematology, Oncology and Palliative Medicine | Obstetrics and Gynecology | Folate receptor | Ovarian cancer | 5-METHYLTETRAHYDROFOLATE | VIVO | ovarian cancer | BINDING-PROTEIN | folate receptor | CELL-GROWTH | OBSTETRICS & GYNECOLOGY | BREAST-CANCER | IN-VITRO | ONCOLOGY | TISSUES | IMAGING AGENTS | EXPRESSION | CARCINOMA | Immunohistochemistry | Folate Receptors, GPI-Anchored | Adenocarcinoma, Mucinous - pathology | Adenocarcinoma, Clear Cell - mortality | Humans | Middle Aged | Cystadenocarcinoma, Serous - metabolism | Gene Expression Regulation, Neoplastic | Ovarian Neoplasms - pathology | Neoplasm Recurrence, Local - drug therapy | Cystadenocarcinoma, Serous - genetics | Ovarian Neoplasms - mortality | Cystadenocarcinoma, Serous - pathology | Neoplasm Recurrence, Local - mortality | Cystadenocarcinoma, Serous - drug therapy | Carcinoma, Endometrioid - metabolism | Neoplasm Recurrence, Local - pathology | Ovarian Neoplasms - genetics | Neoplasm Metastasis | Female | Ovarian Neoplasms - metabolism | Retrospective Studies | Adenocarcinoma, Mucinous - drug therapy | Ovarian Neoplasms - drug therapy | Carcinoma, Endometrioid - genetics | Neoplasm Recurrence, Local - metabolism | Adenocarcinoma, Clear Cell - metabolism | Medical Records | Receptors, Cell Surface - metabolism | Minnesota | Carcinoma, Endometrioid - drug therapy | Adenocarcinoma, Mucinous - mortality | Carrier Proteins - genetics | Disease-Free Survival | Carrier Proteins - metabolism | Carcinoma, Endometrioid - mortality | Adenocarcinoma, Mucinous - metabolism | Survival Analysis | Cystadenocarcinoma, Serous - mortality | Neoplasm Recurrence, Local - genetics | Adenocarcinoma, Clear Cell - pathology | Adenocarcinoma, Mucinous - genetics | Adenocarcinoma, Clear Cell - genetics | Carcinoma, Endometrioid - pathology | Adenocarcinoma, Clear Cell - drug therapy | Receptors, Cell Surface - genetics | Folic acid
Journal Article
Cancer Research, ISSN 0008-5472, 08/2011, Volume 71, Issue 15, pp. 5081 - 5089
Resistance to platinum-based chemotherapy develops in the majority of patients with epithelial ovarian cancer (EOC). Platinum compounds form electrophilic... 
ELEMENTS | GENE | MECHANISM | ONCOLOGY | DIMERIZATION | IDENTIFICATION | PROTEINS | EXPRESSION | NF-E2-Related Factor 2 - physiology | Adenocarcinoma, Clear Cell - mortality | Humans | Neoplasm Proteins - physiology | Ovarian Neoplasms - pathology | Carcinoma - mortality | Antineoplastic Agents, Alkylating - pharmacology | Neoplasm Proteins - antagonists & inhibitors | Cell Line, Tumor - drug effects | Gene Expression Profiling | Ovarian Neoplasms - mortality | Organoplatinum Compounds - pharmacology | Ovarian Neoplasms - genetics | RNA Interference | DNA Mutational Analysis | Female | NF-E2-Related Factor 2 - genetics | Carcinoma - pathology | Neoplasm Proteins - genetics | Intracellular Signaling Peptides and Proteins - genetics | Kelch-Like ECH-Associated Protein 1 | Ovarian Neoplasms - drug therapy | Carcinoma - drug therapy | Intracellular Signaling Peptides and Proteins - antagonists & inhibitors | RNA, Small Interfering - pharmacology | Kaplan-Meier Estimate | Proportional Hazards Models | Signal Transduction - genetics | DNA, Neoplasm - drug effects | Sequence Analysis, DNA | Antineoplastic Agents, Alkylating - therapeutic use | Drug Resistance, Neoplasm - genetics | Carcinoma - genetics | Signal Transduction - physiology | Adenocarcinoma, Clear Cell - pathology | DNA, Neoplasm - genetics | Carboplatin - pharmacology | Intracellular Signaling Peptides and Proteins - physiology | Adenocarcinoma, Clear Cell - genetics | Organoplatinum Compounds - therapeutic use | Adenocarcinoma, Clear Cell - drug therapy
Journal Article
Molecular Cancer Therapeutics, ISSN 1535-7163, 07/2016, Volume 15, Issue 7, pp. 1472 - 1484
Journal Article
Histopathology, ISSN 0309-0167, 01/2013, Volume 62, Issue 1, pp. 59 - 70
The histopathological classification of ovarian surface epithelial carcinomas (referred to hereafter as ‘ovarian carcinoma’) has shifted over the past 10 years... 
ovarian carcinoma | clear cell carcinoma | endometrioid carcinoma | serous carcinoma | mucinous carcinoma | molecular pathology | Mucinous carcinoma | Serous carcinoma | Molecular pathology | Clear cell carcinoma | Ovarian carcinoma | Endometrioid carcinoma | GRADE SEROUS CARCINOMA | PHASE-II | STAGE-I | PATHOLOGY | INTRAEPITHELIAL CARCINOMA | CANCER | MUCINOUS TUMORS | CELL BIOLOGY | POOR-PROGNOSIS | EPITHELIAL TUMORS | CLEAR-CELL CARCINOMA | K-RAS PROTOONCOGENE | Adenocarcinoma - pathology | Cystadenocarcinoma, Mucinous - pathology | Humans | Ovarian Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Cystadenocarcinoma, Serous - genetics | Cystadenocarcinoma, Serous - pathology | Cystadenocarcinoma, Serous - drug therapy | Ovarian Neoplasms - genetics | Cystadenoma, Serous - drug therapy | Biomarkers, Tumor - metabolism | Female | Adenocarcinoma - genetics | Ovarian Neoplasms - drug therapy | Cystadenocarcinoma, Mucinous - genetics | Carcinoma, Endometrioid - genetics | Carcinoma, Endometrioid - drug therapy | Adenocarcinoma - drug therapy | Cystadenocarcinoma, Mucinous - drug therapy | Adenocarcinoma, Clear Cell - pathology | Mutation | Adenocarcinoma, Clear Cell - genetics | Carcinoma, Endometrioid - pathology | Cystadenoma, Serous - genetics | Adenocarcinoma, Clear Cell - drug therapy | Cystadenoma, Serous - pathology | Chemotherapy | Carcinoma | Health aspects | Ovarian cancer | Cancer | Index Medicus
Journal Article